Linvoseltamab In Combination With Carfilzomib Or Bortezomib Shows Promising Initial Results In Earlier Lines Of Treatment For Relapsed/Refractory Multiple Myeloma

RefinitivЗаймёт меньше минуты

Regeneron Pharmaceuticals Inc REGN:

LINVOSELTAMAB IN COMBINATION WITH CARFILZOMIB OR BORTEZOMIB SHOWS PROMISING INITIAL RESULTS IN EARLIER LINES OF TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
REGENERON PHARMACEUTICALS INC - 90% OBJECTIVE RESPONSE RATE IN LINVOSELTAMAB AND CARFILZOMIB COMBINATION

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Чтобы прочитать эту статью, зарегистрируйтесь на TradingView — это бесплатно